This is a request for continuation of a program begun in 1979. Since isolation of gonadotropin releasing hormone (GnRH) in the early 1970s, basic and clinical discoveries have presented uses for GnRH analogs. Among these are treatments for endometriosis/fibroids, polycystic ovary disease, perimenopause, protection of the ovary and testes (i.e., during chemotherapy), assisted reproduction, precocious puberty, male and female birth control, prostatic, ovarian and mammary carcinomas, cryptorchidism, and other conditions. The first GnRH agonist was approved for use in the US in 1985 (Leuprolide (Lupron, TAP/Abbott)); Buserelin (Hoechst) was already in use in Europe at that time. Each of these molecules, and other agonists, continue to be available for international use. Due to patent expirations, they are now sold by various companies and in an array of formulations and delivery systems, adding to their potential utility and comprising a world-wide market in excess of $1.5 billion. Studies of GnRH action have provided a great deal of useful, basic information to the field of neuroendocrine peptides. Among the faciliatory features of GnRH and its analogs are ease of preparing GnRH analog radioligands, availability of model systems with measurable endpoints, the relative specificity of actions, size (i.e., TRH is very small and chemical modifications frequently destroy binding activity, while CRF and GHRH are large and analogs are relatively difficult to synthesize; GnRH is virtually impossible to denature), and availability of vectors encoding the GnRH receptor and many mutants (along with fluorescent probes) from a range of species and tissues. In addition, nearly 10,000 biologically active GnRH analogs are now described in the scientific and patent literature, providing an exquisite database for understanding structure-activity relations; these analogs include well-defined full agonists and full antagonists, many of which are metabolically stable or have other desirable characteristics. Improved understanding of the mechanism of action of this hormone will likely lead to opportunities for improved drugs (i.e., fewer side effects, orally active and cheaper) and more specific therapies. """"""""Non-traditional"""""""" approaches also have potential; approaches involving some of these are described in the present proposal.
The specific aims of this study will advance both our basic understanding and will identify new sites and approaches potentially amenable to therapeutic intervention. ? ?

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Research Project (R01)
Project #
Application #
Study Section
Biochemical Endocrinology Study Section (BCE)
Program Officer
Lamar, Charisee A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
Schools of Medicine
United States
Zip Code
Zarinan, Teresa; Perez-Solis, Marco A; Maya-Nunez, Guadalupe et al. (2010) Dominant negative effects of human follicle-stimulating hormone receptor expression-deficient mutants on wild-type receptor cell surface expression. Rescue of oligomerization-dependent defective receptor expression by using cognate decoys. Mol Cell Endocrinol 321:112-22
Janovick, Jo Ann; Conn, P Michael (2010) Use of pharmacoperones to reveal GPCR structural changes associated with constitutive activation and trafficking. Methods Enzymol 485:277-92
Janovick, Jo Ann; Conn, P Michael (2010) Salt bridge integrates GPCR activation with protein trafficking. Proc Natl Acad Sci U S A 107:4454-8
Ayala Yanez, Rodrigo; Conn, P Michael (2010) Protein disulfide isomerase chaperone ERP-57 decreases plasma membrane expression of the human GnRH receptor. Cell Biochem Funct 28:66-73
Conn, P Michael; Ulloa-Aguirre, Alfredo (2010) Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs. Trends Endocrinol Metab 21:190-7
Re, Michelle; Pampillo, Macarena; Savard, Martin et al. (2010) The human gonadotropin releasing hormone type I receptor is a functional intracellular GPCR expressed on the nuclear membrane. PLoS One 5:e11489
Conn, P Michael; Janovick, Jo Ann (2009) Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease. Mol Cell Endocrinol 299:137-45
Lucca-Junior, W; Janovick, J A; Conn, P M (2009) Participation of the endoplasmic reticulum protein chaperone thio-oxidoreductase in gonadotropin-releasing hormone receptor expression at the plasma membrane. Braz J Med Biol Res 42:164-7
Ulloa-Aguirre, Alfredo; Conn, P Michael (2009) Targeting of G protein-coupled receptors to the plasma membrane in health and disease. Front Biosci (Landmark Ed) 14:973-94
Conn, P Michael; Janovick, Jo Ann (2009) Drug development and the cellular quality control system. Trends Pharmacol Sci 30:228-33

Showing the most recent 10 out of 160 publications